Imprimis Pharmaceuticals to Announce Third Quarter 2018 Financial Results on November 13, 2018
06 November 2018 - 11:00PM
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) today announced it
will release third quarter 2018 financial results after the close
of trading on Tuesday, November 13, 2018. The company will
host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m.
Pacific Time on the same day to discuss the financial results and
recent business developments.
To participate in the call, please dial (877)
407-8031 for domestic callers or (201) 689-8031 for international
callers. To listen to the webcast, please click here or visit
the investor relations section of the Imprimis website by clicking
here. A dial in replay of the call will be available until
December 13, 2018. To access the replay, dial (877) 481-4010
domestically or (919) 882-2331 internationally and reference Replay
ID: 40047. The webcast replay will be available until
February 13, 2019.
About Imprimis
Pharmaceuticals
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is
a commercial-stage pharmaceutical company based in San Diego,
California. In addition to owning the nation’s leading
ophthalmology pharmaceutical compounding business, ImprimisRx, the
Company holds large equity positions in Eton Pharmaceuticals,
Surface Pharmaceuticals and Melt Pharmaceuticals, companies
originally founded as subsidiaries of Imprimis. The Company
also owns royalty rights in certain 505(b)(2) drug candidates being
developed by Eton, Surface and Melt. For more information
about Imprimis, please visit the Investor Relations section of the
corporate website by clicking here.
SAFE HARBOR
This press release contains forward-looking
statements within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Any statements in this release that
are not historical facts may be considered such "forward-looking
statements." Forward-looking statements are based on management's
current expectations and are subject to risks and uncertainties
which may cause results to differ materially and adversely from the
statements contained herein. Some of the potential risks and
uncertainties that could cause actual results to differ from those
predicted include our ability to make commercially available our
compounded formulations and technologies in a timely manner or at
all; physician interest in prescribing our formulations; risks
related to our compounding pharmacy operations; our ability to
enter into other strategic alliances, including arrangements with
pharmacies, physicians and healthcare organizations for the
development and distribution of our formulations; our ability to
obtain intellectual property protection for our assets; our ability
to accurately estimate our expenses and cash burn, and raise
additional funds when necessary; risks related to research and
development activities; the projected size of the potential market
for our technologies and formulations; unexpected new data, safety
and technical issues; regulatory and market developments impacting
compounding pharmacies, outsourcing facilities and the
pharmaceutical industry; competition; and market conditions. These
and additional risks and uncertainties are more fully described in
Imprimis' filings with the Securities and Exchange Commission,
including its Annual Report on Form 10-K and its Quarterly Reports
on Form 10-Q. Such documents may be read free of charge on the
SEC's web site at www.sec.gov. Undue reliance should not be placed
on forward-looking statements, which speak only as of the date they
are made. Except as required by law, Imprimis undertakes no
obligation to update any forward-looking statements to reflect new
information, events or circumstances after the date they are made,
or to reflect the occurrence of unanticipated events.
No Imprimis compounded formulation is
FDA-approved. Other than drugs compounded at a registered
outsourcing facility, all Imprimis compounded formulations require
a prescription for an individually identified patient consistent
with federal and state laws.
CONTACTS
Investor Contact:Jon
Pattonjpatton@imprimispharma.com858-704-4587
Source: Imprimis Pharmaceuticals, Inc.
Imprimis Pharmaceuticals, Inc. (delisted) (NASDAQ:IMMY)
Historical Stock Chart
From May 2024 to Jun 2024
Imprimis Pharmaceuticals, Inc. (delisted) (NASDAQ:IMMY)
Historical Stock Chart
From Jun 2023 to Jun 2024